Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Blinatumomab/Consolidation Chemo Combo Improves OS in MRD-Negative B-cell ALL

December 13th 2022

Blinatumomab followed by consolidation chemotherapy led to a 58% reduction in the risk of death compared with standard consolidation chemotherapy alone in adult patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.

VITAL Post-Hoc Analysis Shows Birtamimab Significantly Improves Time to All-Cause Mortality in Stage IV AL Amyloidosis

December 13th 2022

Birtamimab demonstrated a significant survival benefit in patients with Mayo Stage IV amyloid light chain amyloidosis at month 9.

Dr Topp on the Efficacy of Glofitamab Plus R-CHOP in Previously Untreated DLBCL

December 12th 2022

Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.

Zanubrutinib Demonstrates Efficacy and Safety in Acalabrutinib-Intolerant Patients with B-Cell Malignancies

December 12th 2022

Updated results from the ongoing phase 2 BGB-3111-215 trial showed that zanubrutinib provided clinically meaningful benefit to a large majority of efficacy-evaluable patients with B-cell malignancies who were intolerant to acalabrutinib.

Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura

December 12th 2022

In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.

Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL

December 12th 2022

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.

Low-Dose Lenalidomide Reduces Risk of Transfusion Dependency, Provides Clonal Response and Safety Benefits in MDS

December 12th 2022

Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.

Tisagenlecleucel Elicits Sustained Responses in Relapsed/Refractory Follicular Lymphoma

December 12th 2022

Tisagenlecleucel produced durable responses in patients with relapsed/refractory follicular lymphoma, including those with high-risk disease characteristics.

Mezigdomide Shows Encouraging Activity With Dexamethasone in Heavily Pretreated Patients With Multiple Myeloma

December 11th 2022

Mezigdomide showed notable clinical activity and a manageable safety profile when combined with dexamethasone in patients with triple-class relapsed or refractory multiple myeloma.

Magrolimab Plus Azacitidine and Venetoclax Produces Promising Responses in Newly Diagnosed, High-Risk AML

December 11th 2022

The addition of magrolimab to azacitidine and venetoclax produced high complete response rates and was well tolerated as first-line therapy in patients with high-risk de novo and secondary acute myeloid leukemia regardless of TP53 mutation status.

Crovalimab Achieves Stable Hemolysis Control, Transfusion Avoidance in Paroxysmal Nocturnal Hemoglobinuria

December 11th 2022

Crovalimab led to rapid and stable hemolysis control and transfusion avoidance, with no new safety signals, in Chinese patients with paroxysmal nocturnal hemoglobinuria.

Zanubrutinib Delivers Durable Disease Control in Relapsed/Refractory MZL

December 11th 2022

Zanubrutinib sustained high response rates and led to durable disease control with low incidence of hypertension and atrial fibrillation in patients with relapsed/refractory marginal zone lymphoma, according to findings from the final analysis of the phase 2 MAGNOLIA trial.

Ziftomenib Showcases Clinical Activity, Favorable Tolerability in Relapsed/Refractory AML

December 11th 2022

Ziftomenib monotherapy had a manageable toxicity profile and provided pronounced antileukemic activity when given at a 600-mg dose in heavily pretreated patients with relapsed or refractory acute myeloid leukemia.

Examining Headway in AML and Multiple Myeloma at ASH 2022: Drs Braunstein and Erba

December 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Dr Shadman on Zanubrutinib in Acalabrutinib-Intolerant Patients With B-cell Malignancies

December 11th 2022

Mazyar Shadman, MD, MPH, discusses the examination of zanubrutinib in patients with B-cell malignancies who were intolerant to acalabrutinib.

Pirtobrutinib Shows High Response Rates in Heavily Pretreated Waldenström Macroglobulinemia

December 11th 2022

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.

REGAL Trial Receives Green Light to Continue Testing Galinpepimut-S in AML

December 9th 2022

The phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia will continue as planned without modifications following a recommendation from the Independent Data Monitoring Committee.

Development of Zandelisib for B-cell Malignancies Discontinued Outside of Japan

December 6th 2022

The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.

FDA Grants Breakthrough Therapy Designation to Revumenib in Relapsed/Refractory KMT2A-rearranged Acute Leukemia

December 6th 2022

The FDA has granted a breakthrough therapy designation to revumenib for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Unmet Needs and Future Directions in Care for Relapsed/Refractory FL

December 6th 2022

Closing out her discussion on novel therapy for relapsed/refractory follicular lymphoma, Lori Leslie, MD, highlights unmet needs and considers future evolutions in the treatment paradigm.